# Nexstim Plc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/nexstim). ## Overview Nexstim is a Finnish medical technology company focused on developing non-invasive brain stimulation technologies. The company is known for its pioneering work in transcranial magnetic stimulation (TMS) combined with 3D navigation systems. Nexstim's products are designed to provide precise and individualized stimulation of brain areas, aiding in the diagnosis and treatment of challenging brain disorders. The company's mission is to enhance patient outcomes through innovative diagnostic and therapeutic solutions. ## Products & services • NBS 5 diagnostic system for pre-surgical brain mapping • NBT® system for treating severe depression • NBS 6 therapeutic system for chronic neuropathic pain • Navigated Transcranial Magnetic Stimulation (nTMS) technology • CE-marked and FDA-approved brain mapping solutions - **Diagnostic Systems** (40%) — Includes NBS 5 for brain mapping before surgery - **Therapeutic Systems** (45%) — Includes NBT® and NBS 6 for treating brain disorders - **Research and Neuroscience** (15%) — Involves sales of research devices and licenses - NBS 5 diagnostic system for pre-surgical brain mapping - NBT® system for treating severe depression - NBS 6 therapeutic system for chronic neuropathic pain - Navigated Transcranial Magnetic Stimulation (nTMS) technology - CE-marked and FDA-approved brain mapping solutions ## Customers Nexstim's customers primarily include hospitals, clinics, and research institutions that require advanced brain mapping and stimulation technologies. These entities utilize Nexstim's systems for both diagnostic purposes, such as pre-surgical planning, and therapeutic applications, like treating severe depression and chronic pain. The company's products are particularly valued by neurosurgeons and neurologists for their precision and non-invasive nature. Nexstim also collaborates with academic institutions for research purposes, expanding its reach and application of its technologies. - **Hospitals and Clinics** (primary) — Purchase diagnostic and therapeutic systems for patient care - **Research Institutions** (secondary) — Acquire devices for neuroscience research - **Academic Partnerships** (emerging) — Collaborate on expanding technology applications - Hospitals and clinics use NBS systems for pre-surgical brain mapping - Neurologists and psychiatrists use NBT® for treating severe depression - Research institutions purchase devices for neuroscience studies - Academic partnerships expand technology applications - Clinics value non-invasive, precise brain stimulation solutions ## Geography Nexstim operates primarily in the European Union and the United States, with a growing presence in Asia. The company is headquartered in Finland and has expanded its market reach through strategic partnerships. Nexstim's products are distributed globally, with significant installations in leading hospitals and research centers worldwide. The company continues to explore new markets, particularly in Asia, to increase its global footprint. - Headquartered in Finland with a strong presence in the EU and US - Expanding market reach in Asia through strategic partnerships - Global distribution with installations in leading hospitals - Focus on increasing presence in emerging markets ## Strategy Nexstim's strategic priorities include expanding its market presence in Asia and enhancing its product offerings through innovation. The company focuses on developing new modules for its NBS 6 system, aiming to increase its versatility and application range. Nexstim is committed to strengthening its competitive edge by leveraging its unique navigation technology. The company also aims to grow its clinical and research partnerships to drive long-term shareholder value. - **Expand market presence in Asia** (medium-term) — To increase global footprint and revenue - **Enhance NBS 6 system** (short-term) — To increase product versatility and application - Expand market presence in Asia through strategic partnerships - Develop new modules for NBS 6 to enhance versatility - Leverage unique navigation technology for competitive advantage - Grow clinical and research partnerships for long-term value ## Risks Nexstim faces several risks, including regulatory challenges in obtaining and maintaining approvals for its medical devices. The company is also exposed to competitive pressures from other medical technology firms. Additionally, geopolitical tensions, particularly in Asia, could impact market expansion efforts. Financial risks include fluctuations in currency exchange rates and the need for continued investment in R&D to maintain technological leadership. - **Regulatory challenges** [critical] — Obtaining and maintaining device approvals - **Competitive pressures** [high] — Presence of other medical technology firms - Regulatory challenges in device approvals - Competitive pressures from other medical technology firms - Geopolitical tensions affecting market expansion - Currency exchange rate fluctuations impacting financials - Need for continued R&D investment to maintain leadership ## Accounting Nexstim's financial statements are influenced by several critical accounting matters, including the recognition of revenue from device sales and licensing agreements. The company must carefully manage the timing of revenue recognition to align with delivery and acceptance criteria. Additionally, Nexstim's financial results are subject to fluctuations due to currency exchange rates, given its international operations. The company also faces challenges in estimating provisions for potential liabilities related to regulatory compliance and intellectual property disputes. - **Revenue recognition** — Significant on reported revenue - **Currency fluctuations** — Moderate - Revenue recognition from device sales and licensing agreements - Impact of currency exchange rate fluctuations on financial results - Estimation of provisions for regulatory compliance liabilities - Management of intellectual property dispute provisions --- *Last updated: 2026-08-11T04:04:54.816227+00:00*